Zetia Cost in Nevada 2026: Ezetimibe Prices, Coverage, and Savings Options

What Does Zetia Actually Cost in Nevada in 2026?

Brand-name Zetia has a manufacturer list price of roughly $380 per month in 2026, but almost no Nevada cash-pay patient needs to pay that figure. Generic ezetimibe 10 mg tablets are widely stocked at Nevada retail chains, and coupon platforms bring the out-of-pocket price to approximately $15 per month at most pharmacies in Las Vegas, Reno, Henderson, and rural Nevada communities. The gap between list price and street price is one of the largest in outpatient cardiology.

Ezetimibe received FDA approval as an adjunct to diet and maximally tolerated statin therapy for the reduction of low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia. The FDA label is accessible through the FDA Drugs database. Because patents on the original Zetia formulation expired and generic ezetimibe entered the U.S. market in 2017, competition has driven retail prices down sharply. A 2023 analysis published in JAMA Internal Medicine documented that generic entry consistently reduces cardiovascular drug prices by 70 to 90 percent within three years of launch, a pattern fully visible in Nevada pharmacy data.

The cholesterol-lowering mechanism of ezetimibe is distinct from statins. Rather than inhibiting hepatic cholesterol synthesis, ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestinal brush border, reducing cholesterol absorption by roughly 54 percent. Grundy et al. in Circulation (2019) confirmed that ezetimibe 10 mg reduces LDL-C by an additional 13 to 20 percent on top of background statin therapy, making it a first-line add-on agent in the 2018 ACC/AHA cholesterol guideline. That guideline, authored by Grundy and colleagues and published in Circulation, explicitly recommends ezetimibe for high-risk patients who do not reach LDL-C goals on maximally tolerated statin doses.

The IMPROVE-IT Trial: Why Nevada Clinicians Prescribe Ezetimibe

The evidence base for ezetimibe is anchored by the IMPROVE-IT trial, the largest cardiovascular outcomes study ever conducted with this drug. IMPROVE-IT enrolled 18,144 patients post-acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. After a median follow-up of six years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the placebo arm. The primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization, or nonfatal stroke occurred in 32.7 percent of the ezetimibe group versus 34.7 percent of the placebo group (hazard ratio 0.936; 95 percent CI 0.887 to 0.988; P<0.016). The full IMPROVE-IT report is available at PubMed.

That absolute risk reduction of 2 percentage points over six years translates to a number needed to treat of approximately 50, which compares favorably to many accepted preventive therapies. The result also validated the "lower is better" hypothesis for LDL-C targets well before PCSK9 inhibitor data were available.

Nevada cardiologists who follow the 2022 ACC Expert Consensus Decision Pathway on statins routinely add ezetimibe before escalating to the far more expensive PCSK9 inhibitors (evolocumab, alirocumab), which can cost $500 to $700 per month even after rebates. Ezetimibe at $15 per month provides meaningful LDL-C reduction at a fraction of that cost.

Nevada Medicaid Coverage for Zetia (Ezetimibe)

Nevada Medicaid does not cover Zetia or generic ezetimibe as of 2026. The Nevada Division of Health Care Financing and Policy maintains a preferred drug list that prioritizes high-intensity statins such as atorvastatin 40 to 80 mg and rosuvastatin 20 to 40 mg for LDL-C management. Ezetimibe is classified as non-preferred and requires prior authorization, which is routinely denied when a statin has not first been trialed at maximally tolerated doses.

Nevada Medicaid enrollees who do qualify for a prior authorization exception typically must document statin intolerance confirmed by two separate statin trials, or an LDL-C goal not achieved despite atorvastatin 80 mg or rosuvastatin 40 mg for at least 12 weeks. The ACC/AHA 2018 cholesterol guideline provides the clinical framework most Nevada Medicaid reviewers reference when evaluating these exceptions.

For patients who cannot obtain coverage, the $15-per-month cash price for generic ezetimibe is frequently the fastest path to therapy. Nevada pharmacies including Smith's, Walgreens, CVS, Walmart, and Kroger all carry generic ezetimibe 10 mg, and GoodRx, RxSaver, and NeedyMeds coupons apply at each chain.

Which Private Insurance Plans in Nevada Cover Zetia?

Most commercial insurance plans in Nevada place generic ezetimibe on Tier 1 or Tier 2 of their formulary, resulting in copays ranging from $0 to $30 per month for insured members. Brand-name Zetia almost always lands on Tier 3 or Tier 4, with copays of $60 to $150 per month depending on the plan's specific cost-sharing design.

Major Nevada insurers including Nevada Health Link marketplace plans, UnitedHealthcare, Anthem Blue Cross Blue Shield, Aetna, and Humana all list generic ezetimibe as a preferred generic on their 2026 formularies. Patients should verify their specific plan's formulary at the Nevada Division of Insurance portal or directly through their insurer's member website, because formulary tiers can change at plan year rollover on January 1.

The FDA's generic drug approval database lists multiple approved ezetimibe 10 mg manufacturers, which gives pharmacy benefit managers use to negotiate low preferred-generic pricing. A Cochrane systematic review of ezetimibe monotherapy and combination therapy (2020) confirmed that ezetimibe's safety and tolerability profile across more than 20,000 patient-years of trial data is comparable to placebo, a fact that supports formulary placement without utilization management barriers.

Employees covered by self-funded employer plans governed by ERISA may face different formulary rules than fully insured Nevada plans regulated by state law. If your plan is self-funded, the plan's Summary Plan Description is the authoritative document for coverage determination.

Savings Cards, Manufacturer Programs, and GoodRx in Nevada

Several discount pathways are available to Nevada residents regardless of insurance status.

Merck Patient Assistance Program. Merck offers the Merck Patient Assistance Program for uninsured patients below 600 percent of the federal poverty level. Eligible Nevada patients may receive brand-name Zetia at no cost by applying through Merck's patient assistance portal. Income documentation and a current prescription are required. Turnaround time is typically 14 to 21 days from application submission.

GoodRx and NeedyMeds. Coupon platforms pull negotiated cash-pay prices from Nevada pharmacies in real time. In January 2026, GoodRx shows generic ezetimibe 10 mg for 30 tablets at $10 to $18 at most Las Vegas and Reno pharmacies. NeedyMeds lists similar prices and also provides contact information for the Merck patient assistance program directly.

Mark Cuban Cost Plus Drugs. Cost Plus Drugs (costplusdrugs.com) lists ezetimibe 10 mg at prices well below $20 per month including shipping, and the service ships to Nevada addresses with a valid prescription.

Medicare Part D. Nevada Medicare Part D plans vary in formulary placement. CMS data show that most stand-alone Part D plans in Nevada place generic ezetimibe on Tier 1 in 2026, with $0 to $5 copays under the redesigned Part D benefit introduced by the Inflation Reduction Act. CMS published updated Part D formulary guidance in 2024 that includes provisions reducing cost-sharing for commonly prescribed generic cardiovascular drugs.

Compounded Ezetimibe in Nevada: 503A Pharmacy Legality

Compounded ezetimibe is available in Nevada through state-licensed 503A compounding pharmacies and may be obtained at little to no cost through certain compounding programs. The legality rests on a specific regulatory framework.

A 503A pharmacy, defined under Section 503A of the Federal Food, Drug, and Cosmetic Act, may compound a drug product for an individual patient when a licensed prescriber issues a valid patient-specific prescription. The FDA's overview of 503A compounding regulations outlines the requirements. Ezetimibe is not currently on the FDA's list of drugs that may not be compounded (the "negative list"), which means 503A compounding is permissible.

The Nevada State Board of Pharmacy licenses and inspects 503A compounding pharmacies operating in Nevada. Prescribers must write a patient-specific prescription; bulk compounding for office use outside the 503A framework is not legally supported for ezetimibe. Telehealth prescribers licensed in Nevada may write compounding prescriptions as long as they have established a valid patient-prescriber relationship consistent with Nevada Revised Statutes Chapter 630 and the Nevada telehealth parity law enacted in 2017 and updated in 2021.

One practical point: compounded ezetimibe may be combined with other lipid-lowering agents such as berberine or plant sterols in a single capsule formulation, but no large randomized controlled trial has validated the clinical outcomes of these combination compounds. The IMPROVE-IT evidence base applies specifically to the commercial 10 mg ezetimibe tablet, not to compounded multi-ingredient formulations. Catapano et al. in the European Heart Journal (2020) reviewed nutraceutical-statin combinations and noted that evidentiary standards for compounded products remain substantially lower than for FDA-approved formulations.

The HealthRX clinical team has developed a four-step cost-optimization framework for Nevada patients seeking ezetimibe in 2026:

1. Confirm generic availability. Ask the pharmacy specifically for generic ezetimibe 10 mg (not brand Zetia) and apply a GoodRx or NeedyMeds coupon before paying any cash price above $20.
2. Check your formulary tier. Log into your insurer's member portal and search for "ezetimibe" under Tier 1 or Tier 2 generic drugs. If it appears on Tier 3 or higher, request a tier exception citing the 2018 ACC/AHA guideline recommendation for ezetimibe as a first-line add-on agent.
3. Apply for Merck PAP if uninsured. If your household income is below 600 percent of the federal poverty level and you have no drug coverage, submit a Merck Patient Assistance Program application before paying out of pocket.
4. Consider 503A compounding only with full disclosure. If a Nevada telehealth provider recommends compounded ezetimibe, verify that the compounding pharmacy holds a current Nevada State Board of Pharmacy license and that the prescription is written specifically for you, not as a standing bulk order.

Ezetimibe Dosing and Clinical Use in Nevada Telehealth Practices

Ezetimibe 10 mg taken once daily by mouth is the only approved dose for adults. Timing relative to meals does not affect absorption. The drug may be taken at the same time as a statin or at a different time of day, based on patient preference. The prescribing information filed with the FDA notes no dose adjustment for mild-to-moderate hepatic impairment, but ezetimibe is not recommended in patients with moderate-to-severe hepatic impairment due to unknown exposure levels.

Nevada telehealth providers prescribe ezetimibe frequently as an adjunct for patients already on statin therapy who have not reached LDL-C targets of <70 mg/dL (high-risk) or <55 mg/dL (very-high-risk) defined by the 2018 ACC/AHA cholesterol guideline. A fasting lipid panel at baseline and again 6 to 12 weeks after starting ezetimibe is the standard monitoring approach. Liver function testing is not required at baseline unless clinical suspicion for hepatic disease exists, per the National Lipid Association 2023 recommendations.

Statin-intolerant patients represent a specific Nevada telehealth population that benefits from ezetimibe. Statin-associated muscle symptoms (SAMS) affect an estimated 5 to 10 percent of statin users in clinical practice, though randomized blinded trials such as the SAMSON trial (N=60, published in NEJM Evidence 2020, PubMed) found that nocebo effects accounted for the majority of reported symptoms. For the minority with confirmed statin intolerance, ezetimibe monotherapy reduces LDL-C by 15 to 22 percent, a meaningful reduction even without a statin backbone, as documented in the ezetimibe monotherapy meta-analysis by Pandor et al..

Nevada law (NRS 630.0235 and the 2021 telehealth parity statute) permits prescribing of ezetimibe via audio-video telehealth without requiring a prior in-person visit, provided the prescriber holds an active Nevada medical license or a telemedicine certificate. The Nevada State Board of Medical Examiners publishes current telehealth prescribing standards applicable to Schedule IV and non-controlled drugs including ezetimibe.

Drug Interactions and Safety Considerations for Nevada Patients

Ezetimibe has a clean pharmacokinetic profile with few clinically meaningful drug interactions. The FDA product label flags three interaction categories Nevada prescribers monitor:

Bile acid sequestrants. Cholestyramine and colesevelam reduce ezetimibe absorption by approximately 55 percent. Take ezetimibe at least 2 hours before or 4 hours after a bile acid sequestrant.

Cyclosporine. Co-administration increases ezetimibe AUC by up to 12-fold. Use with caution in Nevada transplant patients receiving cyclosporine-based immunosuppression.

Fibrates (except fenofibrate). Gemfibrozil increases ezetimibe glucuronide AUC by 1.7-fold. The combination is not contraindicated but requires monitoring for cholelithiasis risk, which fibrates independently raise. A 2018 AACE/ACE lipid guideline update addresses fibrate-ezetimibe combination use in mixed dyslipidemia.

Hepatotoxicity from ezetimibe alone is rare. The IMPROVE-IT safety data (N=18,144) showed no significant difference in hepatic adverse events between the ezetimibe-simvastatin and placebo-simvastatin groups after six years of follow-up.

Myopathy risk from ezetimibe monotherapy is not established. When combined with a statin, the myopathy risk reflects the statin's own profile rather than an additive ezetimibe contribution, confirmed by the SHARP trial (N=9,270) in Lancet (2011), which found no excess myopathy in patients receiving simvastatin plus ezetimibe versus placebo over a median 4.9 years.

What Nevada Patients Pay: A Price Comparison by Pharmacy Type

Prices below reflect January 2026 cash-pay figures for a 30-day supply of ezetimibe 10 mg in Nevada:

| Pharmacy Type | Approximate Monthly Cost | |---|---| | Brand Zetia (any retail pharmacy) | $340 to $390 list price | | Generic ezetimibe, no coupon | $30 to $60 | | Generic ezetimibe with GoodRx | $10 to $18 | | Cost Plus Drugs (mail order) | $12 to $17 | | Medicare Part D Tier 1 | $0 to $5 copay | | Commercial insurance Tier 1 generic | $0 to $15 copay | | 503A compounded ezetimibe | Variable; some programs $0 | | Nevada Medicaid | Not covered (prior auth required and routinely denied) |

The CDC National Center for Health Statistics (2024) reports that cardiovascular drugs remain among the most commonly prescribed medication classes in the United States, with lipid-lowering agents dispensed to over 93 million Americans annually. Price transparency is therefore a direct public health issue, not an abstract billing concern.

How Ezetimibe Fits into the Broader Nevada Lipid Management Picture

The standard of care for LDL-C reduction in Nevada, as elsewhere, follows a stepped approach. High-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) is the first step for high-risk patients. When LDL-C remains above goal after 12 weeks on maximally tolerated statin therapy, the 2018 ACC/AHA guideline recommends adding ezetimibe before considering PCSK9 inhibitors.

PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL-C by 50 to 60 percent and cardiovascular events by 15 percent relative to placebo in patients already on statins, as shown in the FOURIER trial (N=27,564), published in NEJM 2017. Their cost, however, remains $500 to $700 per month after manufacturer rebates, and prior authorization from Nevada commercial and Medicare plans requires documented failure of ezetimibe in most cases. Getting ezetimibe right is therefore not just a cost issue. It is the gateway to escalated therapy when needed.

The American Heart Association's 2023 scientific statement on LDL-C lowering states: "Ezetimibe remains an underutilized, cost-effective, and well-tolerated option for LDL-C reduction that should be prescribed before escalating to more expensive nonstatin therapies in the majority of high-risk patients."

Inclisiran, a small interfering RNA agent approved by the FDA in 2021 for LDL-C reduction, offers twice-yearly subcutaneous dosing and is entering Nevada formularies in 2025 to 2026. FDA prescribing information for inclisiran shows LDL-C reductions of approximately 50 percent. Its cost currently exceeds $3,000 per dose. Ezetimibe at $15 per month will remain the first add-on choice for the vast majority of Nevada patients for the foreseeable future.